Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma ; volume:7 ; number:1 ; day:21 ; month:10 ; year:2019 ; pages:1-12 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (21.10.2019), 1-12, 12.2019
- Urheber
-
Rajan, Arun
Heery, Christopher R.
Thomas, Anish
Mammen, Andrew L.
Perry, Susan
O’Sullivan Coyne, Geraldine
Guha, Udayan
Berman, Arlene
Szabo, Eva
Madan, Ravi A.
Ballester, Leomar Y.
Pittaluga, Stefania
Donahue, Renee N.
Tsai, Yo-Ting
Lepone, Lauren M.
Chin, Kevin
Ginty, Fiona
Sood, Anup
Hewitt, Stephen M.
Schlom, Jeffrey
Hassan, Raffit
Gulley, James L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0723-9
- URN
-
urn:nbn:de:101:1-2020021523314992991091
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rajan, Arun
- Heery, Christopher R.
- Thomas, Anish
- Mammen, Andrew L.
- Perry, Susan
- O’Sullivan Coyne, Geraldine
- Guha, Udayan
- Berman, Arlene
- Szabo, Eva
- Madan, Ravi A.
- Ballester, Leomar Y.
- Pittaluga, Stefania
- Donahue, Renee N.
- Tsai, Yo-Ting
- Lepone, Lauren M.
- Chin, Kevin
- Ginty, Fiona
- Sood, Anup
- Hewitt, Stephen M.
- Schlom, Jeffrey
- Hassan, Raffit
- Gulley, James L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Programmed death-ligand 1 (PD-L1) expression in various tumor types
Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Regulation des Programmed cell death ligand 1 (PD-L1) auf Phagozyten durch den alternativen Aktivierungsweg des Komplementsystems
Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
Untersuchung des solublen Programmed Cell Death Ligand 1 (sPD-L1) Plasmaspiegels bei Patienten mit paroxysmaler nächtlicher Hämoglobinurie und der Programmed Cell Death Ligand 1 (PD-L1) Expression bei in vitro Komplementaktivierung
Clinical significance of checkpoint regulator “Programmed death ligand-1 (PD-L1)” expression in meningioma: review of the current status